Stocks › ARQT
Arcutis Biotherapeutics, Inc.
ARQT·Nasdaq·
United States·USD
$26.36
-0.81 (-2.98%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ARQT
Arcutis Biotherapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ARQTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ARQT by members of U.S. Congress · 6 on record · 3 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr.House · D · CA |
ARQTArcutis Biotherapeutics, Inc. · Stock |
Purchase $1,001 - $15,000 |
Jun 8, 2026 | May 29, 2026 | Filing ↗ |
Gilbert Ray Cisneros, Jr.House · D · CA |
ARQTArcutis Biotherapeutics, Inc. · Stock |
Purchase $1,001 - $15,000 |
Apr 7, 2026 | Mar 3, 2026 | Filing ↗ |
Gilbert Ray Cisneros, Jr.House · D · CA |
ARQTArcutis Biotherapeutics, Inc. · Stock |
Sale $1,001 - $15,000 |
Jan 12, 2026 | Dec 11, 2025 | Filing ↗ |
Josh GottheimerHouse · D · NJ |
ARQTArcutis Biotherapeutics, Inc. · Stock |
Sale $1,001 - $15,000 |
Oct 15, 2023 | Sep 15, 2023 | Filing ↗ |
Josh GottheimerHouse · D · NJ |
ARQTArcutis Biotherapeutics, Inc. · Stock |
Purchase $1,001 - $15,000 |
May 19, 2023 | Apr 17, 2023 | Filing ↗ |
Josh GottheimerHouse · D · NJ |
ARQTArcutis Biotherapeutics, Inc. · Stock |
Purchase $1,001 - $15,000 |
Jul 22, 2022 | Jun 15, 2022 | Filing ↗ |
Whale Activity
Position changes in ARQT reported for 2026-09-30 by 332 institutional filers
- Increased122
- New59
- Held34
- Decreased67
- Closed38
- No prior filing12
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 19.2M | $506.7M | increased |
| MONTANOVA CAPITAL, LLC | 12.3M | $324.3M | decreased |
| Frazier Life Sciences Management, L.P. | 9.9M | $261.0M | held |
| Rubric Capital Management LP | 8.4M | $222.6M | increased |
| STATE STREET CORP | 7.7M | $204.0M | increased |
| Polar Capital Holdings Plc | 6.6M | $174.2M | decreased |
| UBS Group AG | 5.5M | $146.2M | increased |
| MORGAN STANLEY | 5.3M | $140.0M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.0M | $132.0M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.8M | $100.9M | increased |
| BANK OF AMERICA CORP /DE/ | 3.5M | $92.3M | increased |
| JENNISON ASSOCIATES LLC | 3.3M | $88.1M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ARQT insiders, by quarter · Form 4
Recent Insider Transactions
689 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Welgus Howard G.Director · Director | Sale | −4,728 | $28.16 | $133K | Nov 16, 2026 | Form 4 ↗ |
| Matsuda MasaruEVP, Chief Legal Officer | Sale | −40.0K | $34.32 | $1.4M | Nov 4, 2026 | Form 4 ↗ |
| Matsuda MasaruEVP, Chief Legal Officer | Sale | −1,219 | $31.86 | $39K | Nov 2, 2026 | Form 4 ↗ |
| Burnett PatrickEVP, Chief Medical Officer | Sale | −943 | $31.86 | $30K | Nov 2, 2026 | Form 4 ↗ |
| Watanabe ToddSee Remarks · Director | Sale | −4,377 | $31.86 | $139K | Nov 2, 2026 | Form 4 ↗ |
| Welgus Howard G.Director · Director | Sale | −4,728 | $26.93 | $127K | Oct 15, 2026 | Form 4 ↗ |
| Matsuda MasaruSee Remarks | Sale | −3,674 | $25.00 | $92K | Sep 16, 2026 | Form 4 ↗ |
| Welgus Howard G.Director | Sale | −4,730 | $24.18 | $114K | Sep 15, 2026 | Form 4 ↗ |
| Welgus Howard G.Director | Option exercise | +2,255 | $8.63 | $19K | Sep 15, 2026 | Form 4 ↗ |
| Welgus Howard G.Director | Option exercise | +1,019 | $7.51 | $8K | Sep 15, 2026 | Form 4 ↗ |
| Welgus Howard G.Director | Option exercise | +822 | $6.52 | $5K | Sep 15, 2026 | Form 4 ↗ |
| Matsuda MasaruSee Remarks | Sale | −9,989 | $25.03 | $250K | Sep 8, 2026 | Form 4 ↗ |
| Curran TerrieDirector | Sale | −27.1K | $25.03 | $677K | Aug 27, 2026 | Form 4 ↗ |
| Curran TerrieDirector | Option exercise | +27.1K | $8.63 | $233K | Aug 27, 2026 | Form 4 ↗ |
| Curran TerrieDirector | Sale | −11.1K | $25.03 | $279K | Aug 27, 2026 | Form 4 ↗ |
| Curran TerrieDirector | Option exercise | +11.1K | $7.51 | $84K | Aug 27, 2026 | Form 4 ↗ |
| Curran TerrieDirector | Sale | −1,072 | $26.04 | $28K | Aug 20, 2026 | Form 4 ↗ |
| Curran TerrieDirector | Option exercise | +1,072 | $7.51 | $8K | Aug 20, 2026 | Form 4 ↗ |
| Burnett PatrickSee Remarks | Sale | −1,697 | $27.00 | $46K | Aug 19, 2026 | Form 4 ↗ |
| Welgus Howard G.Director | Sale | −4,730 | $26.18 | $124K | Aug 17, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ARQT · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.6M | $93.5M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.9M | $77.0M | 0.09% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 2.9M | $76.4M | 0.71% | Jun 30, 2026 |
| Small Cap Growth Fund American Century Mutual Funds, Inc. | 1.5M | $39.4M | 0.71% | Jul 31, 2026 |
| PGIM Jennison Small Company Fund Prudential Jennison Small Co Fund, Inc. | 1.4M | $36.3M | 1.04% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.3M | $34.3M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.3M | $33.6M | 0.10% | Jul 31, 2026 |
| Oberweis Small-Cap Opportunities Fund OBERWEIS FUNDS | 1.2M | $31.8M | 1.12% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 1.1M | $27.7M | 0.18% | Jun 30, 2026 |
| BARON DISCOVERY FUND BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 867.4K | $22.7M | 1.24% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ARQT's shares (CUSIP 03969K108), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 7.7M shares6.1%
Nov 10, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 17.8M shares14.1%
Oct 5, 2026 · ↗ - Polar Capital LLPSCHEDULE 13G · passive (13G) · 6.6M shares5.3%
Aug 14, 2026 · ↗ - Polar Capital Holdings PlcSCHEDULE 13G · passive (13G) · 6.6M shares5.3%
Aug 14, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 5.8M shares4.7%
Aug 7, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 6.3M shares5.1%
May 12, 2026 · ↗ - PRUDENTIAL FINANCIAL INCSCHEDULE 13G/A · passive (13G) · 5.3M shares4.3%
May 8, 2026 · ↗ - Jennison Associates LLCSCHEDULE 13G/A · passive (13G) · 5.0M shares4.0%
May 6, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming arcutis biotherapeutics as client
Government Contracts
Federal awards to Arcutis Biotherapeutics, Inc. · USAspending
No federal contract awards found for Arcutis Biotherapeutics, Inc..
U.S. Patents
Recent USPTO applications naming Arcutis Biotherapeutics, Inc.
No USPTO patent applications found for Arcutis Biotherapeutics, Inc..
Annual Financials
From ARQT's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $376.1M | $196.5M | $59.6M | $3.7M | n/a |
| Operating income | -$12.2M | -$128.4M | -$241.1M | -$301.6M | -$206.5M |
| Net income | -$16.1M | -$140.0M | -$262.1M | -$311.5M | -$206.4M |
| Diluted EPS | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 |
| Operating cash flow | -$5.6M | -$112.2M | -$247.1M | -$257.7M | -$174.6M |
| Cash and equivalents | $42.9M | $71.3M | $88.4M | $53.6M | $96.4M |
| Total assets | $433.0M | $348.9M | $341.4M | $449.3M | $408.2M |
| Total liabilities | $243.5M | $191.3M | $252.7M | $239.7M | $110.5M |
| Shareholders' equity | $189.5M | $157.5M | $88.7M | $209.6M | $297.7M |
As Arcutis Biotherapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 25, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in ARQT's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureOct 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 5.02, 9.01Results of operations · Officer / director changeAug 5, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureJul 16, 2026
EDGAR ↗ - 8-K · Items 5.07, 8.01, 9.01Shareholder vote · Other eventsJun 9, 2026
EDGAR ↗ - 8-K · Items 9.01May 6, 2026
EDGAR ↗
About Arcutis Biotherapeutics, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersWESTLAKE VILLAGE, CA
IncorporatedDE
SEC CIK0001787306 ↗
Former namesArcutis, Inc.


